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A B S T R A C T
Aim: This study aimed to investigate the association between salivary levels of myeloperoxidase (MPO), neu-
trophil elastase (NE), soluble urokinase-type plasminogen activator receptor (suPAR), matrix metalloproteinase
(MMP)-8 and tissue inhibitor of matrix metalloproteinases (TIMP)-1 and gingival inﬂammation development
during an experimental gingivitis study.
Methods: A three-week experimental gingivitis study was conducted. Clinical recordings of dental plaque bioﬁlm
(Modiﬁed Quigley Hein Plaque Index, TQHPI) and gingival inﬂammation (Modiﬁed Gingival Index, MGI) were
made at speciﬁc time points for each of the 42 participants. Salivary levels of MPO, NE, suPAR, MMP-8 and
TIMP-1 at the same time points were measured using distinct immunoassays. For data analysis growth curve
modelling was employed to account for the time-varying outcome (MGI score) and the time-varying covariates
(salivary marker levels, and TQHPI score). Analyses were stratiﬁed according to the MGI-score trajectory groups
previously identiﬁed as ‘fast’, respectively ‘slow’ responders.
Results: Overall, higher MGI scores were statistically signiﬁcantly positively associated with higher levels of
MPO, MMP-8 and TIMP-1. Stratiﬁed analysis according to inﬂammation development trajectory group revealed
higher levels of salivary MPO, MMP-8 and MMP-8/TIMP-1 ratio among the ‘fast’ responders than among ‘slow’
responders. None of the investigated salivary protein markers was associated with a ‘slow’ inﬂammation de-
velopment response.
Conclusions: Salivary levels of MPO, MMP-8 and TIMP-1 were associated with the extent and severity of gingival
inﬂammation. While the ‘fast’ gingival inﬂammation response was associated with increased levels of MPO,
MMP-8 and MMP-8/TIMP-1 ratio, the ‘slow’ response was not associated with any of the salivary protein
markers investigated in this study. Neutrophil activity seems to orchestrate a ‘fast’ gingival inﬂammatory re-
sponse among participants previously primed to gingival inﬂammation.
1. Introduction
Current understanding of the etiopathogenesis of periodontal dis-
eases recognizes the host immune response as a key factor in the onset
and progression of periodontal diseases [1]. In essence, a host immune-
inﬂammatory response is elicited as a response to dysbiotic plaque
accumulation, with local proinﬂammatory cytokines and chemokines
attracting neutrophils to the infection site [2]. In an attempt to control
tissue invasion by bacteria, neutrophils release myeloperoxidase (MPO)
and elastase (NE), which in turn activate matrix metalloproteinases
(MMPs) [3]. Local activation of MMPs may lead to periodontal de-
struction if the MMP is not inactivated by speciﬁc regulators, such as
the tissue inhibitor of matrix metalloproteinases (TIMP)-1 [4]. In per-
iodontal research, MMP-8 is one of the most frequently investigated
MMPs, since the MMP-8/TIMP-1 relationship is closely related to per-
iodontal tissue destruction [5]. Stimulated neutrophils also release
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suPAR (soluble urokinase-type Plasminogen Activator Receptor), a
chemotactic agent related to the recruitment of other immune cells to
the inﬂamed site [6].
While many attempts have been made to identify distinct response
patterns in gingivitis development, most of these present methodolo-
gical caveats, such as neglect of the data structure and the longitudinal
study design, what has precluded a deeper understanding of the factors
involved in the health-gingivitis dynamics [7]. In a recent experimental
gingivitis study, we were able to identify two diﬀerent patterns of
gingival inﬂammation development dubbed ‘fast’ and ‘slow’ response
[8]. Whilst the ‘fast’ responders seemed capable of responding rapidly
to bioﬁlm accumulation, the ‘slow’ responders presented a lagged de-
velopment of gingival inﬂammation for the same bioﬁlm insult [8].
Even though individual variation in the susceptibility to develop
gingivitis has been intensively discussed, the mechanisms involved in
this process remain unclear. Previous observations of individual var-
iation in the gingival response patterns to experimental plaque accu-
mulation have loosely been attributed to diﬀerences in “individual
subject’s resistance” [9], but no further investigation has been carried
out of the role played by the immune response. The study of key protein
markers involved in the inﬂammatory response may therefore be
helpful in clarifying the diﬀerent patterns of gingival inﬂammation
responses to experimental plaque accumulation. For that reason, the
present study aimed to investigate the association between salivary
levels of MPO, NE, suPAR, MMP-8 and TIMP-1 and the patterns of
development of gingival inﬂammation during a period of experimental
plaque accumulation.
2. Methods
2.1. Experimental gingivitis study
Participants for this experimental gingivitis study were recruited
among students of Aarhus University. Eligibility criteria included age
between 18 and 35 years, a minimum of 20 teeth present, no pocket
probing depth> 4mm, and no evidence of interproximal clinical at-
tachment loss> 2mm. Individuals were excluded if they had used
antibiotics or anti-inﬂammatory medications within the previous six
weeks, had systemic conditions interfering with the immune system, or
had retentive factors for plaque in the form of orthodontic appliances,
crowns, bridgework, or inadequate restorations. Exclusion criteria also
included pregnancy (current or planned), breastfeeding, or any im-
pairment that precluded eﬀective personal oral hygiene.
Participation was based on written informed consent and the study
was approved by the Ethical Committee of the Central Denmark Region
(j.nr. 1-10-72-402-14). Volunteers who agreed to participate in the
study were invited to a screening visit that comprised clinical ex-
aminations and information collected with the use of a questionnaire.
This visit aimed to evaluate the individuals’ eligibility for the experi-
mental phases of the study. Self-reported information on smoking was
also gathered and validation of the self-reported smoking status in-
formation was done by quantifying salivary cotinine using a high sen-
sitivity enzyme-linked immunosorbent assay (ELISA) assay (Salimetrics
Europe Ltd., Newmarket, UK).
The study comprised three phases: A two-week run-in Hygiene
Program Phase; a three-week experimental plaque accumulation
Induction Phase; and a two-week Resolution Phase. Individuals who
fulﬁlled the eligibility criteria were enrolled in the two-week Hygiene
Program. This program aimed to reduce plaque and calculus deposits
and gingival inﬂammation prior to the Induction Phase. The program
comprised at least two visits, in which plaque was disclosed, supra- and
subgingival plaque and calculus removed, and oral hygiene instructions
provided. Throughout the Hygiene Program, all participants were in-
structed to perform oral hygiene twice daily with standard toothbrush
and toothpaste provided by the researchers. Individuals were permitted
to proceed to the Induction Phase when they had achieved bleeding on
probing< 4% on all units examined and visible plaque< 20% of all
units examined.
During the Induction Phase, the participants were instructed to
abstain from all oral hygiene procedures for three weeks. Participants
were speciﬁcally asked not to use other oral hygiene products, in-
cluding chewing gum, mouth rinse solutions or dental ﬂoss. When the
three-week experimental Induction Phase was completed, all partici-
pants were supplied with a toothbrush and toothpaste to reestablish
self-performed oral hygiene. At the end of the two-week Resolution
Phase, after examinations have been conducted, a professional cleaning
was provided to participants who required additional care to restore
gingival health.
The Modiﬁed Quigley Hein Plaque Index (TQHPI) was used for
plaque recordings [10], and the Modiﬁed Gingival Index (MGI) was
used for clinical recordings of gingival inﬂammation [11]. Plaque was
recorded in the papillary and marginal units of each tooth from the
buccal aspect, leading to a maximum of 56 recordings per participant;
while recordings of gingival inﬂammation were also done from the
lingual/palatal aspect, leading to a maximum of 112 recordings per
participant. Clinical recordings were performed at days 0, 7, 14, 21 and
35.
2.2. Saliva sampling
All saliva samples were collected in the morning between 8 AM and
10 AM. Participants were asked to avoid eating, drinking and per-
forming oral hygiene for two hours before the visit. Prior to the saliva
collection, participants rinsed their mouth with water twice, and waited
ﬁve minutes after rinsing to avoid saliva dilution. Saliva was obtained
by passive drooling for ﬁve minutes in a sterile 50 mL polypropylene
conic tube. Saliva was aliquoted, stored, and frozen at −80 °C (for
suPAR analyses) or at −20 °C (for all other markers).
2.3. Neutrophil elastase, MPO, TIMP-1 and MMP-8 assessment
The concentrations of salivary neutrophil elastase, MPO and TIMP-1
were determined by commercially available enzyme-linked im-
munosorbent assay (ELISA) kits according to the manufacturer’s pro-
tocol as described by Akcali et al. [12]. The detection limit was 1.98 pg/
mL using human Neutrophil Elastase Platinum ELISA (Bender Med-
Systems, Vienna, Austria), 1.6 ng/mL using MPO ELISA Kit (Im-
mundiagnostik, Bensheim, Germany), and 1.25 ng/mL using Amersham
TIMP-1, human Biotrak ELISA system (Amersham Biosciences, Little
Chalfont, UK). The saliva MMP-8 levels were analysed by time-resolved
immunoﬂuorometric assay (IFMA) (Medix Biochemica, Espoo, Finland)
with the detection limit of 0.08 ng/mL. The molar ratios of MMP-8/
TIMP-1 were calculated and converted to mol/L [13].
2.4. suPAR assessment
Concentrations of salivary suPAR were measured in duplicate using
an automated ELISA robot (suPARnostic AUTO Flex Kit, Lot. No.
204LA1-1; Virogates, Birkerød, Denmark). The assay detection limit
was 1 ng/mL. Prior to analysis, samples were centrifuged at 5000g for
10min at 4 °C, and then diluted 1:1 in assay dilution buﬀer.
2.5. Data analysis
Individual mean TQHPI and MGI scores were calculated for each
time point of the study. Group-based-trajectory-modelling was applied
to model patterns of development in MGI scores over time during the
three-week Induction Phase [14]. This analytical approach allowed us
to identify two groups of participants who follow distinctly diﬀerent
patterns of gingival inﬂammation development under the study period;
one group dubbed ‘slow’ responders, and one dubbed ‘fast’ responders.
Detailed information on this analysis can be found elsewhere [8].
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Fig. 1. Log10 transformed levels of (A) MMP-8, ng/ml; (B) TIMP-1, ng/ml; (C) MMP-8/TIMP-1 ratio, mol ratio; (D) MPO, ng/ml; (E) NE, ng/ml; (F) suPAR, ng/ml.
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The data set available for analysis consisted of data on salivary
protein markers, gingival inﬂammation (MGI) scores and dental plaque
bioﬁlm (TQHPI) scores for each of the time points day 0, 7, 14, and 21.
Such data lend themselves to execute growth curve modelling as mul-
tilevel mixed-eﬀects regression analysis at individual level, in order to
account for the time-varying clinical outcome (the MGI score) and the
time-varying covariates (salivary marker levels, TQHPI score) being
nested within each individual. Levels of salivary protein markers were
log10 transformed due to non-normal distribution and over-dispersion
(Fig. 1). In order to allow comparability between salivary protein
markers and MGI score, all variables were standardized to a mean value
of 0 and a standard deviation of 1.
Initially, we attempted to run a single model simultaneously in-
cluding all salivary protein markers as independent variables. However,
the large standard errors observed indicated model misspeciﬁcation,
and given the sample size studied and the resulting lack of degrees of
freedom, we therefore decided to carry out analytical models using one
marker at a time. Multilevel analyses were adjusted for plaque accu-
mulation and stratiﬁed by ‘fast’ and ‘slow’ gingival inﬂammation re-
sponse.
3. Results
Forty-two participants [64.3% females, mean age 23.8 yr (SD
3.6 yr)] were enrolled and completed all three-study phases. None of
the participants reported smoking, and this was conﬁrmed by the
salivary cotinine ELISA assay results (data not shown). Table 1 sum-
marizes the clinical data and the salivary protein marker observations
for all participants. TQHPI and MGI scores increased gradually and
continually over the Induction Phase (days 0, 7, 14 and 21) and had
returned to much lower levels at the end of the Resolution Phase (day
35). As evidenced by the comparatively large standard deviations of the
observations for all six protein markers considered, the distributions
showed pronounced skewness, which led us to stratify the data by the
previously identiﬁed inﬂammatory development pattern (Table 2).
Evidently, ‘fast’ responders presented higher salivary levels of all mar-
kers than did ‘slow’ responders. However, although some reduction in
the standard deviations was seen, skewness was still apparent, and this
led us to log10 transform these data (Fig. 1) prior to further analysis.
The results of multilevel modelling of the eﬀect of time and the
standardized TQHPI score on the standardized MGI score are presented
in Table 3, both for the overall sample and for the two inﬂammatory
development pattern groups.
When salivary protein marker levels were added to the mixed-ef-
fects multilevel models presented in Table 3, the coeﬃcients shown in
Table 4 revealed that overall, increased levels of salivary myeloperox-
idase, elastase, MMP-8 and TIMP-1 were associated with gingival in-
ﬂammation (Table 4). However, analyses stratiﬁed according to the
inﬂammatory development pattern showed that the overall contrasts
were essentially attributable to the ‘fast’ responders, who had statisti-
cally higher levels of salivary myeloperoxidase, MMP-8 and MMP-8/
TIMP-1 molar ratio during the Induction Phase, where this was not the
case for the ‘slow’ responders. None of the investigated protein markers
was associated with the ‘slow’ response pattern (Table 4).
The predicted relationship between salivary protein markers and
Table 1
Mean values (SD) of the scores for the clinical parameters TQHPI and MGI, and
of the concentrations of the salivary markers in the samples according to Day of
Experiment. Given for the total study group (n=42).
Day of experiment (n= 42)
0 7 14 21 35
Clinical Data
TQHPI score 0.14
(0.1)
1.59
(0.5)
2.52
(0.5)
3.01
(0.4)
0.57
(0.3)
MGI score 0.01
(0.0)
0.49
(0.3)
1.34
(0.4)
1.85
(0.3)
0.17
(0.2)
Salivary Markers
Elastase
(ng/mL)
211.8
(260.3)
162.0
(182.2)
222.5
(335.5)
249.5
(313.9)
200.9
(185.4)
MPO
(ng/mL)
3808.8
(2854.3)
4529.6
(6389.1)
4771.2
(4178.5)
4590.0
(4763.7)
4223.2
(3490.7)
suPAR
(ng/ml)
12.0
(8.7)
11.8
(13.0)
12.0
(11.6)
10.7
(6.9)
11.0
(8.7)
MMP-8
(ng/mL)
687.7
(704.7)
616.9
(602.8)
677.2
(652.8)
736.5
(579.1)
897.0
(744.3)
TIMP-1
(ng/mL)
542.8
(430.0)
479.6
(326.6)
525.1
(307.9)
459.6
(303.0)
451.6
(300.2)
MMP-8/TIMP-1
(mol ratio)
0.57
(0.5)
0.56
(0.5)
0.54
(0.5)
0.73
(0.7)
0.80
(0.6)
Table 2
Mean values (SD) of the scores for the clinical parameters TQHPI and MGI, and of the concentrations of the salivary markers in the samples according to Day of
Experiment. Data presented according to the ‘fast’ and the ‘slow’ gingival inﬂammation development patterns.
Gingival inﬂammation development pattern
‘Slow’ responders (n=27)
Day of experiment
‘Fast’ responders (n= 15)
Day of experiment
0 7 14 21 35 0 7 14 21 35
Clinical Data
TQHPI score 0.13
(0.1)
1.35
(0.4)
2.46
(0.5)
2.94
(0.4)
0.56
(0.3)
0.17
(0.1)
1.84
(0.4)
2.64
(0.5)
3.04
(0.3)
0.60
(0.3)
MGI score 0.01
(0.0)
0.32
(0.1)
1.22
(0.3)
1.77
(0.3)
0.11
(0.1)
0.02
(0.0)
0.80
(0.2)
1.56
(0.4)
2.01
(0.2)
0.29
(0.3)
Salivary Markers
Elastase
(ng/mL)
123.4
(125.9)
129.6
(164.2)
150.7
(224.4)
141.4
(127.2)
147.2
(142.7)
371.0
(356.1)
220.5
(203.5)
351.9
(456.3)
444.0
(445.3)
293.9
(217.3)
MPO
(ng/mL)
3088.3
(2434.8)
4271.2
(7733.8)
3669.2
(3127.6)
3233.3
(1961.8)
3558.7
(3462.7)
5105.6
(3169.7)
4994.5
(2847.6)
6754.6
(5138.9)
7032.1
(7026.3)
5419.8
(3321.9)
suPAR
(ng/ml)
9.4
(7.3)
9.6
(12.8)
9.7
(9.0)
8.7
(5.8)
9.2
(8.7)
16.6
(9.4)
15.8
(12.9)
16.3
(14.7)
14.3
(7.5)
14.4
(7.8)
MMP-8 (ng/mL) 484.5
(617.6)
494.5
(557.0)
528.2
(627.0)
529.2
(466.3)
780.1
(776.9)
1053.3
(723.2)
837.3
(638.0)
945.5
(631.0)
1109.9
(588.2)
1107.6
(653.7)
TIMP-1
(ng/mL)
403.3
(289.8)
372.5
(278.1)
416.6
(260.5)
385.7
(252.8)
379.5
(293.2)
793.9
(529.6)
672.4
(326.8)
720.4
(296.7)
592.6
(347.4)
581.2
(276.1)
MMP-8/TIMP-1
(mol ratio)
0.55
(0.6)
0.57
(0.6)
0.55
(0.5)
0.59
(0.7)
0.80
(0.7)
0.60
(0.4)
0.54
(0.4)
0.54
(0.3)
0.97
(0.8)
0.81
(0.3)
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gingival inﬂammation at each time point of the Induction Phase is
presented in Fig. 2. This ﬁgure shows that time was far more inﬂuential
for the MGI score than was any of the salivary markers although weak
positive correlations were observed for all markers except suPAR.
4. Discussion
The results of the present study have revealed an association be-
tween myeloperoxidase and MMP-8 and the development of gingivitis
in response to plaque accumulation. Neutrophil activity, expressed as
levels of myeloperoxidase in saliva, was associated with a ‘fast’ clinical
gingival response to plaque accumulation over the Induction Phase.
Furthermore, an imbalance in the MMP-8/TIMP-1 molar ratio was also
observed among the ‘fast’ responders, explained by increased levels of
MMP-8. Conversely, the ‘slow’ response was not associated with any of
the salivary markers under investigation in this study.
Leukocytes, especially neutrophils play a pivotal role in the or-
chestration of the inﬂammatory response. During the early phase of
gingivitis development, neutrophils are the ﬁrst line cells to perform
phagocytosis in an attempt to neutralize the bioﬁlm challenge [12].
Nevertheless, persistent neutrophil stimulation may lead to exacerbated
production of inﬂammatory components, which may initiate tissue
destruction [12]. A latent form of MMP-8 (proMMP-8) is released from
secondary granules of neutrophils and other cells, such as plasma cells,
ﬁbroblasts and gingival sulcular epithelial cells [15]. Proinﬂammatory
cytokines, neutrophil elastase and myeloperoxidase, among others,
seem to induce and activate the latent MMP-8 [16]. While MPO sti-
mulates the production of reactive oxygen species (ROS), which will in
turn upregulate the activation of proMMP-8, and downregulate TIMP-1,
neutrophil elastase directly activates proMMP-8 by proteolytic cleavage
[17]. Neutrophils are also responsible for perpetuating the in-
ﬂammatory response, because the insult cannot be readily eliminated.
The production of elastase and suPAR by the neutrophils later in the
inﬂammatory response is responsible for tissue remodelling and che-
motaxis of other immune cells, respectively [6].
Host-derived inﬂammatory protein markers such as proin-
ﬂammatory cytokines and enzymes, including myeloperoxidase, elas-
tase and MMPs, are produced and accumulate as a response to plaque
accumulation. Primed neutrophils tend to respond more rapidly when
de novo exposed to plaque, being capable of instantly organizing an
inﬂammatory reaction, which, in turn, may lead to early clinical signs
of gingival inﬂammation [18]. We have shown that having higher mean
scores of gingival inﬂammation at the day of screening for inclusion in
this study was associated with a ‘fast’ response to plaque accumulation
during the Induction Phase [8]. This indicates that the gingival in-
ﬂammatory background might have primed the neutrophils. ‘Fast’ re-
sponders presented higher levels of all salivary markers at day 0 even
after achieving a clinical situation of gingival health prior to the com-
mencement of the Induction Phase (Table 1).
Our results showed that the levels of both MMP-8 and TIMP-1 were
positively associated with gingival inﬂammation in a similar magni-
tude, therefore, not changing the balance between MMP-8 and its in-
hibitor. But as TIMP-1 inhibits all MMPs, MMP8 activity is most likely
elevated, assuming that the levels of other MMPs remain constant.
However, among the ‘fast’ responders, the results indicate that while
the levels of MMP-8 increased as gingivitis developed, the levels of
TIMP-1 did not follow the same course. This may explain the imbalance
found in the MMP-8/TIMP-1 molar ratio noted among the ‘fast’ re-
sponders only. In a cross-sectional study, Noack et al. found that in-
dividuals with gingivitis presented higher salivary levels of MMP-8 than
periodontally healthy individuals, but lower levels than found among
those with periodontitis [19]. This indicates that MMP8 levels are
closely related to the degree of tissue destruction. The increased levels
of MMP-8 observed among the ‘fast’ responders may be a consequence
of the increase in myeloperoxidase levels, which oxidatively upregu-
lates the activation of proMMP-8 [4].
As expected, we did not ﬁnd an association between gingival in-
ﬂammation development and neutrophil elastase and suPAR. According
to Uitto et al., elastase activity is not a reliable indicator of gingivitis
[20]. Even though a peak of elastase is expected in the ﬁrst days of
gingivitis development, levels of elastase tend to decrease after few
days of plaque accumulation [21]. In order to restrain the excessive
self-damaging eﬀect of elastase, alpha-1 protease inhibitor (α1P1) and
secretory leukocyte protease inhibitor (SLPI) are secreted in the saliva
[22]. Nevertheless, increasing levels of elastase occur in periodontitis,
therefore, reinforcing the role of this marker as an indicator of con-
nective tissue destruction. Similarly, levels of suPAR are more pro-
nounced in later – more chronic – stages of the inﬂammatory response,
Table 3
Results of modelling the outcome standardized mean MGI as a random growth curve function of standardized mean TQHPI score and Day of experiment. Estimates
given are the regression coeﬃcients with their respective 95% conﬁdence intervals (95%CI). Results in bold indicate statistical signiﬁcance.
Total Sample (n= 42) ‘Slow’ responders (n= 27) ‘Fast’ responders (n= 15)
Coeﬃcient (95% CI) Coeﬃcient (95% CI) Coeﬃcient (95% CI)
Induction Phase Mean TQHPI score 0.55 (0.37;0.74) 0.35 (0.14;0.55) 0.60 (0.37;0.83)
Day (ref. day 0)
Day 7 −0.02 (−0.23;0.15) 0.04 (−0.17;0.25) 0.15 (0.00;0.37)
Day 14 0.59 (0.23;0.96) 0.88 (0.42;1.33) 0.74 (0.23;1.25)
Day 21 1.03 (0.57;1.49) 1.45 (0.89;2.02) 1.10 (0.54;1.58)
Resolution Phase Day 35 0.00 (−0.10;0.10) 0.00 (−0.07;0.07) 0.11 (−0.08;0.32)
Table 4
Results of modelling the outcome standardized mean MGI as a random growth curve function of each standardized salivary marker at a time. Estimates given are the
regression coeﬃcients with their respective 95% conﬁdence intervals (95%CI). Analyses were adjusted for standardized mean TQHPI score. Results in bold indicate
statistical signiﬁcance.
Salivary Markers Total Sample (n= 42) ‘Slow’ responders (n= 27) ‘Fast’ responders (n= 15)
Coeﬃcient (95% CI) Coeﬃcient (95% CI) Coeﬃcient (95% CI)
Myeloperoxidase 0.09 (0.00;0.18) 0.00 (−0.09;0.09) 0.12 (0.00;0.24)
Elastase 0.05 (0.00;0.10) −0.01 (−0.09;0.08) 0.05 (−0.01;0.10)
suPAR 0.02 (−0.04;0.08) −0.03 (−0.11;0.05) 0.02 (−0.06;0.10)
MMP-8 0.07 (0.01;0.14) 0.04 (−0.02;0.12) 0.07 (0.00;0.15)
TIMP-1 0.06 (0.01;0.12) 0.05 (−0.01;0.11) 0.04 (−0.03;0.10)
MMP-8/TIMP-1 ratio 0.05 (−0.02;0.12) 0.04 (−0.02;0.11) 0.10 (0.00;0.20)
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Fig. 2. Predicted standardized mean MGI score as a function of standardized levels of (A) MMP-8, ng/ml; (B) TIMP-1, ng/ml; (C) MMP-8/TIMP-1 ratio, mol ratio; (D)
MPO, ng/ml; (E) NE, ng/ml; (F) suPAR, ng/ml. Predictive values are presented for the Induction Phase only.
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due to the chemotactic function of suPAR to attract other immune cells
to the inﬂamed site. Such a function is more time-dependent, explaining
why suPAR levels are higher in periodontitis cases. This is further
supported by Skottrup et al. who found a positive association between
suPAR and periodontitis among adolescents [23].
This study demonstrates that salivary levels of myeloperoxidase,
and MMP-8 and TIMP-1 are associated with gingival inﬂammation.
However, a ‘fast’ gingival inﬂammation development to plaque accu-
mulation was associated with increased levels of myeloperoxidase and
the imbalance between MMP-8 and TIMP-1. The ‘slow’ response to
plaque accumulation was not associated with any of the salivary protein
markers investigated in this study. Overall, our results indicate that
neutrophil activity orchestrates a ‘fast’ gingival inﬂammatory response
among participants previously primed to gingival inﬂammation.
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